New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 16, 2012
07:07 EDTARWRArrowHead Research receives allowance for patent for DPC
Arrowhead Research announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office, or USPTO, for patent application U.S. 13/032,029 entitled, " Compositions for Targeted Delivery of siRNA." The patent broadly covers compositions, methods, and uses for a new formulation of Arrowhead's Dynamic Polyconjugate, or DPC, siRNA delivery platform, where attachment of siRNA and delivery vehicle is not required to produce high-level, efficient knockdown of target genes. The new IP expands the DPC platform and is used in Arrowhead's ARC-520 candidate in development for chronic hepatitis B virus infection.
News For ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
10:12 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: VNET GME ARWR GMCR SGMS DSW DANG ARUN JMEI MBLY
November 18, 2014
07:32 EDTARWRArrowhead files for regulatory permission to begin Phase I ARC-AAT trial
Arrowhead Research recently filed an application for approval to begin a Phase 1 clinical trial of its RNAi-based therapeutic candidate, ARC-AAT, for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Pending approval, Arrowhead intends to proceed with a double blind, placebo-controlled dose escalation, Phase 1 study to determine the safety, tolerability, pharmacokinetics and effect on circulating alpha-1 antitrypsin levels of ARC-AAT in healthy volunteers and patients with alpha-1 antitrypsin deficiency. The study is planned to start in Australia in healthy volunteers and will dose escalate until predetermined levels of alpha-1 antitrypsin reduction are reached. Once these levels of protein knockdown are achieved, the study will transition into a population of patients with ZZ genotype alpha-1 antitrypsin deficiency to further evaluate escalating doses of ARC-AAT. The study is designed to enroll up to 48 subjects, including healthy volunteers and alpha-1 antitrypsin deficiency patients. The application was submitted to an ethics committee in compliance with the Clinical Trial Notification process of the Australian Department of Health and Ageing, Therapeutic Goods Administration.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use